COVID-19 Infection and Guillain-Barre Syndrome: A Case Series

Guillan-barre syndrome during COVID-19 pandemic: a case series from Syria

The Coronavirus was first discovered in December 2019 and quickly it turned into a pandemic called coronavirus disease 2019 (COVID-19). The main symptoms of infection with this virus were constitutional and respiratory symptoms. However, one-third of COVID-19 patients also developed neurologic manifestations, including Guillan-Barre syndrome (GBS), which was one of the most critical complications.

Case presentation

In this paper, the authors present seven patients who suffered from GBS after being infected with the Coronavirus or in conjunction with the infection. Nerve conduction studies showed axonal type in four patients, and demyelinating type in three patients. Neurological symptoms were the initial symptoms in two patients and the presence of COVID-19 was later discovered. Most of the patients had an excellent recovery.

Conclusion

In the medical literature, many articles have mentioned the association of GBS with the Coronavirus, and it is considered the most common peripheral neurologic complication for the virus, but this article is considered one of the very few articles that were published from the Middle East, especially from Syria. Guillain-Barre's occurrence after infections is known, and the Coronavirus is one of the most important viruses of the era, which incited an increase in the number of Guillain-Barre patients.

Chronic Inflammatory Demyelinating Polyneuropathy Post-mRNA-1273 Vaccination

Massive efforts are being made to develop coronavirus disease 2019 (COVID-19) vaccines at an unprecedented rate. The vaccinations' adverse impact profile, on the other hand, has not been well established. Neurological complications are increasingly reported as a result of these vaccines. One such complication identified is immune-mediated inflammatory polyneuropathy, which affects peripheral nerves and neurons. We report a case of chronic inflammatory demyelinating polyneuropathy (CIDP) post-mRNA-1273 (Moderna) COVID-19 vaccine. Recognizing this complication and distinguishing it from Guillain-Barré syndrome enables timely initiation of treatment. Additionally, our report highlights a possible link between vaccination and subsequent development of CIDP, but conclusive evidence of a causal relationship requires more extensive studies.